Implementing new treatment strategies in MS

This is the non-PPA version of the course. If you would prefer to take the PPA version of the course please click here

Faculty

Professor Patrick Vermersch, Vice Dean, University of Lille, CHRU de Lille, Lille International Research Inflammation Centre (LIRIC), Lille, France

Professor Antonio Uccelli, Professor of Neurology, Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Università di Genova, Italy

Professor Tobias Derfuss, Professor of Medicine and Senior Physician, Departments of Neurology and Biomedicine at University Clinic, Basel, Switzerland

Professor Gavin Giovannoni, Chair of Neurology, Blizard Institute, Queen Mary University of London, London, United Kingdom

Course overview

The programme covers newer treatment strategies in MS, how they work, and how to implement them into clinical practice. This six module e-learning course includes content from the UEMS/EACCME-accredited meeting “Integrating Innovations in the Treatment of Multiple Sclerosis into Clinical Practice” to enhance the interactive online learning modules.

Target audience

This educational activity is intended for any healthcare professionals involved in the treatment of patients with multiple sclerosis

Learning objectives

Upon completing of the programme, participants should be able to:

Understand the evolution of the multiple sclerosis treatment landscape over the last 25 years, in particular how our evolving understanding of the disease has guided the development of new therapies

Describe the current and new strategies for treating multiple sclerosis, including the use of new agents

Identify the risks and benefits of these treatment strategies when implementing them in daily practice

Funding

This programme has been partly supported by an independent educational grant from Merck KGaA, Darmastadt, Germany

Accreditation

An application has been made to the UEMS EACCME for CME accreditation of this course

Pre-learning Survey
The purpose of this survey is to understand gaps in the current knowledge of clinicians treating patients with multiple sclerosis (MS), and their adoption of newer treatment strategies, especially since several new drugs have become available in recent years.

The data from this survey and the one following completion of modules 1–6 will be used to measure the effectiveness of the programme. All data will be anonymized when used for reporting purposes.
- Take the Pre-learning Survey Questionnaire
Learning Modules 1-6
Post-learning Survey
The purpose of this survey is to measure any change in understanding and practice after completing the learning in modules 1–6.
- Take the Post-learning Survey Questionnaire
  Restricted Not available unless:
  The activity Module 2: The evolving view of neuroinflammation in MS is marked complete
  The activity Module 4: Newer immunomodulatory therapies in MS is marked complete
  The activity Module 5: Immune reconstitution therapy is marked complete
  The activity Module 3: Mechanisms of action: newer MS therapies is marked complete
  The activity Module 6: Case Studies is marked complete
Evaluation Survey
In order to claim your certificate, please complete this evaluation form. It will assist us in evaluating the effectiveness of this activity and planning future educational offerings.

This programme has been submitted to UEMS-EACCME^® for accreditation. If you have completed the programme before accreditation has been awarded, your certificate will be updated and you will be notified.
- Take the evaluation survey Questionnaire
  Restricted Not available unless: The activity Take the Post-learning Survey is marked complete
Certificate
- Certificate Custom certificate CC
  Restricted Not available unless: The activity Take the evaluation survey is marked complete

Faculty

Course overview

Target audience

Learning objectives

Funding

Accreditation

Pre-learning Survey

Learning Modules 1-6

Post-learning Survey

Evaluation Survey

Certificate